May 22, 2020 / 5:13 AM / 10 days ago

BRIEF-Roche Says Data Reinforce Safety Of Satralizumab In Neuromyelitis Patients

May 22 (Reuters) - Roche Holding AG:

* NEW LONGER-TERM DATA REINFORCE SAFETY OF ROCHE’S SATRALIZUMAB IN ADULTS AND ADOLESCENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER

* POOLED DATA FROM TWO PIVOTAL PHASE III OPEN-LABEL EXTENSION (OLE) STUDIES SHOW SATRALIZUMAB WAS WELL-TOLERATED AS A MONOTHERAPY

* ADOLESCENTS TREATED WITH SAME DOSING AND FREQUENCY DEMONSTRATED A BENEFIT-RISK PROFILE GENERALLY CONSISTENT WITH ADULT POPULATION

* NEW DATA FURTHER SUPPORT SATRALIZUMAB AS A POTENTIAL TREATMENT OPTION FOR NMOSD, A RARE, DEBILITATING CONDITION Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below